Thailand PGT CMS

博客

  • What the Numbers and Letters in a Blastocyst Grade Actually Describe

    If you have been given an embryo report, you may have seen a short code such as 4AA, 3BB or 5AB. It looks like a score, but it is closer to a description. A blastocyst grade records what an embryologist observed about an embryo’s shape and structure at a particular moment. It is a morphological description, not a measurement of the embryo’s chromosomes and not a prediction of whether a transfer will lead to a pregnancy.

    The notation is compact because it packs three observations into a few characters. Once you know what each position refers to, the code becomes readable rather than mysterious.

    The three parts of the notation

    Most blastocyst grading systems used in IVF laboratories follow a similar logic. A leading number describes the embryo’s stage of development and expansion. Two letters follow: the first describes the inner cell mass, and the second describes the trophectoderm.

    Position in the code What it describes What the reader is being told
    Leading number Expansion and hatching stage How large the blastocoel cavity is and whether the embryo is beginning to hatch from its outer shell
    First letter Inner cell mass How tightly packed and clearly defined the cluster of cells that will form the fetus appears
    Second letter Trophectoderm How organised and continuous the outer cell layer that will form the placenta appears

    So in a code like 4AB, the 4 refers to expansion, the A to the inner cell mass and the B to the trophectoderm. The letters are usually read from best to poorest appearance, commonly A, B and C, though the exact wording of each category is set by the laboratory.

    What the leading number describes

    The number reflects how far the blastocyst has developed. Early blastocysts have a small cavity; later ones have a large, expanded cavity; and the highest numbers describe an embryo that is hatching or has hatched from the zona pellucida, the protective outer layer.

    Many laboratories use a scale running from 1 to 6, where 1 indicates an early blastocyst and 6 indicates a hatched blastocyst. The important point is that this number is about developmental stage, not quality in the abstract. A day-5 embryo and a day-6 embryo may sit at different points on the scale simply because they were observed at different times.

    What the first letter describes

    The inner cell mass is the group of cells that will develop into the fetus. The first letter records how that cluster looks: whether the cells are numerous, tightly packed and clearly visible, or fewer, looser or harder to make out. An A usually means a well-defined, compact inner cell mass; lower letters describe a less organised appearance.

    What the second letter describes

    The trophectoderm is the outer layer of cells that will contribute to the placenta. The second letter records how that layer looks: whether it forms a cohesive, orderly sheet of many cells, or whether it is sparse, irregular or patchy. Again, A generally describes the most organised appearance and lower letters describe progressively less organised ones.

    Reading the code as a whole

    The three parts are not added up into a single score. A 4AA and a 3AA share the same letter grades but describe embryos at different expansion stages. A 4AB and a 4BA both have one A and one B, but the letters refer to different structures, so they are not interchangeable.

    When you read your own report, it helps to ask three separate questions: what stage was the embryo at, how did the inner cell mass look, and how did the trophectoderm look? Keeping the parts separate avoids the trap of treating the code as a single mark out of ten.

    Why the same embryo can receive different grades

    Grading is a judgement made by a person looking through a microscope at a specific time. Laboratories differ in how they define each category, when they observe embryos, and how they word their reports. Two laboratories looking at comparable embryos may therefore use different letters, and the same embryo observed on different days may move up the expansion scale as it grows.

    This is one reason a grade should be read alongside the laboratory’s own key rather than compared directly with a code from a different clinic. If you are comparing explanations between laboratories, it is reasonable to ask each one how it defines its categories. A published guide on comparing embryo grading explanations between IVF laboratories walks through that comparison.

    What a grade does and does not predict

    A grade describes appearance. It does not read the embryo’s chromosomes, and it cannot confirm that an embryo is genetically normal or that a transfer will succeed. Morphology and genetic testing can tell different stories about the same embryo, which is why a good-looking embryo can still have an abnormal chromosome result and a lower-graded embryo can test normally.

    If you are considering preimplantation genetic testing, the relevant question is separate from grading. PGT-A assesses chromosome number in cells sampled from an embryo, and the test has limitations: it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child. Whether to use it is a decision to discuss for your individual situation with your treating clinician and a genetic counsellor. A guide to reading your PGT-A results after IVF explains how those reports are usually laid out, and a companion piece on embryo appearance versus genetic test results explores why the two kinds of information can diverge.

    It is also worth remembering that a biopsy itself carries a risk: the HFEA notes that embryo biopsy can cause damage and prevent further development. That risk belongs in the conversation about whether testing is right for you, not in the grade itself.

    Questions worth bringing to your clinician

    You are entitled to ask your treating team to walk through your own report. Useful questions include:

    • Which grading system does this laboratory use, and what does each number and letter mean in its key?
    • On which day was this embryo observed, and how does that affect the expansion number?
    • How does this grade relate to the decision you are recommending for my transfer?
    • If PGT was performed, how should I read the grade and the genetic result together?

    These are clinical questions, and they are best answered by the clinicians who know your history and the laboratory’s conventions. A coordination service can help you organise records and prepare questions, but it does not interpret results or recommend treatment.

    Keeping your records straight

    Embryo reports often arrive as a short message or a PDF with several codes. Before a consultation, it helps to note the date of each report, the day of embryo development, and the exact code as written, rather than a remembered summary. If you are preparing for a remote consultation from abroad, a dated record checklist and a list of outstanding documents make the conversation more efficient. A broader set of questions to ask about embryo quality can help you decide what matters most to you.

    None of this changes the core point: the numbers and letters are a description of appearance, written in shorthand. They are useful information, but they are not a verdict.

    Sources: Embryo biopsy can cause damage and prevent further development. — HFEA PGT-A frequently asked questions (checked 2026-10-15).

    Frequently asked questions

    Does a higher blastocyst grade mean the embryo is genetically normal?

    No. A grade describes how the embryo looks under a microscope. It does not assess chromosomes. Genetic status is addressed by a separate test such as PGT-A, which has its own limitations and should be discussed with your clinician and a genetic counsellor.

    Why did my embryo's grade change between reports?

    The leading number reflects developmental stage, so an embryo can move along the expansion scale as it grows between observations. Letter grades are also judgements made by an embryologist at a particular time, and laboratories define their categories differently.

  • MACS vs Routine Sperm Preparation: What the Difference Means for Your IVF Cycle

    If your clinic has mentioned MACS alongside your IVF or ICSI cycle, the first thing to understand is that it is not a different way of preparing a semen sample from scratch. Routine preparation and MACS answer two different questions. Routine preparation asks, “Can we separate motile, clean sperm from seminal fluid and debris?” MACS asks, “Can we further reduce the share of sperm showing surface signals linked to cell damage?”

    In most laboratories that offer it, MACS is layered on top of routine preparation rather than replacing it. That single point explains most of the practical differences in workflow, timing and cost.

    What routine semen preparation actually does

    Before IVF or ICSI, the embryology laboratory has to move sperm out of the raw ejaculate and into a small volume of culture medium. Two methods are commonly described:

    • Density gradient preparation. The sample is layered over solutions of different densities and spun. Motile, structurally intact sperm tend to pass into the denser layer, while seminal fluid, debris and many non-motile cells stay behind. The sperm fraction is then washed.
    • Swim-up preparation. Motile sperm are allowed to swim upward into overlaid culture medium, leaving less motile cells and debris below. The medium containing the swimmers is collected.

    Both methods concentrate motile sperm and remove seminal plasma, which matters because seminal fluid can interfere with fertilisation in the dish. Laboratories choose between them, or combine them, based on the sample and their own protocols. This is standard semen analysis and preparation for IVF territory, and it happens in every cycle that uses fresh or thawed sperm.

    Where MACS fits in

    MACS stands for magnetic-activated cell sorting. In the sperm context, the sample is incubated with tiny magnetic beads carrying a marker that binds to certain surface signals. According to the UK fertility regulator, HFEA guidance on sperm DNA fragmentation and sperm selection, MACS uses magnetic sorting to separate sperm by surface signals associated with damaged or dying cells. Sperm carrying those signals are retained or diverted, and the remaining fraction is collected.

    That is a different sorting principle from density or swim-up. Density gradient and swim-up sort mainly by how well sperm move and how intact they look under the microscope. MACS sorts by a surface marker, which is not the same as proving the DNA inside is normal. A sperm can look and swim well and still carry DNA damage, and a marker-based sort is a proxy, not a direct readout.

    A side-by-side comparison

    Feature Routine preparation (density gradient, swim-up) MACS
    Main sorting principle Motility, density and removal of seminal fluid and debris Surface signals associated with damaged or dying cells
    Position in the workflow The standard first step before IVF or ICSI Usually applied after routine preparation, as an additional step
    What it does not do Does not specifically target DNA-damaged sperm Does not replace washing, concentration or the standard preparation step
    Extra laboratory time Part of the normal laboratory schedule Adds incubation and sorting time, so the laboratory needs to plan for it
    Sample requirements Standard ejaculate or thawed sample Needs enough sperm after routine preparation to run the sort; very low counts may limit feasibility
    Cost Included in the standard laboratory fee Typically quoted as a separate add-on; confirm what the quote includes

    The table describes the general logic of each method. It does not tell you which one your clinic will use, because that depends on the sample, the clinic’s protocols and what has been discussed with you.

    What the evidence does and does not show

    This is the part that deserves the most caution. HFEA assesses sperm selection including MACS, following sperm DNA fragmentation testing, as having insufficient moderate- or high-quality evidence for improved chances of having a baby in male-factor infertility. In other words, the technique has a plausible laboratory rationale, but the clinical benefit is not established to the standard a regulator would want before calling it proven.

    HFEA also notes that sperm DNA fragmentation test methods and interpretations are not standardised. That matters because a fragmentation result is often the reason MACS gets raised in the first place. If the test itself varies between laboratories, the threshold for offering a selection add-on will vary too.

    None of this means MACS is harmful or that a clinic offering it is doing something wrong. It means the honest position is: this is an optional laboratory step with a biological rationale and limited outcome evidence. Whether it is worth adding to your cycle is a clinical and personal judgement, not a settled fact.

    Questions worth putting to your clinician

    These are clinical questions, and a licensed clinician is the right person to answer them for your case. A coordinator can help you get the answers in writing, but cannot advise on whether MACS is appropriate for you.

    • Is MACS offered at this laboratory, and is it performed in-house or referred elsewhere?
    • What is the laboratory’s own experience with the technique, and how does it validate the sorting step?
    • Which patients is it proposed for here, and what would make you recommend it in my case?
    • Would you suggest sperm DNA fragmentation testing first, and how do you interpret the result given the lack of standardisation?
    • Does adding MACS change the quoted package, and what exactly does the additional fee cover?
    • If the post-preparation sperm count is too low on the day, what is the fallback plan?

    Ask for the answers in writing where possible. A written reply is easier to compare across clinics and easier to revisit later if your plan changes.

    How this fits into a PGT cycle

    If you are planning preimplantation genetic testing, the sperm sample still goes through routine preparation before fertilisation, and MACS, if used, sits inside that laboratory workflow. PGT itself is performed on embryos later, and it has its own limits: it is not a guarantee of pregnancy or of a healthy child, and it is not necessary for every patient. The partner and sperm requirements checklist is a useful place to see how the male side of a PGT cycle is organised, including what records and samples the clinic may request.

    It also helps to separate two decisions that often get bundled together: whether to add a sperm-selection step, and whether to add PGT. They are independent choices with independent evidence bases, and a clinic should be able to explain each one on its own terms.

    A practical planning example

    Suppose a couple is preparing for a PGT cycle in Thailand and the male partner has had a sperm DNA fragmentation result from home. They want to know whether MACS should be added. A sensible sequence looks like this:

    1. Collect the existing semen analysis and fragmentation reports, with dates and the name of the laboratory that issued them.
    2. Ask the clinic, before travelling, whether it offers MACS, how it is priced, and whether the fragmentation result would change its recommendation.
    3. Request a remote consultation so a clinician can review the reports and explain the options, including the option of not adding MACS. Remote IVF consultation can cover this kind of review, though some assessments still need a visit.
    4. Ask for the quotation to show the standard preparation and any add-on as separate lines, so you can see what changes if you decline.
    5. Keep a short written record of what was agreed, so the plan is clear when you arrive.

    This is where coordination help is genuinely useful: organising records, sending written questions, requesting the appointment and keeping track of what has been confirmed versus what is still open. It is not a substitute for the clinician’s judgement about your sample or your cycle.

    The short answer

    Routine preparation is the standard washing and concentration step that every IVF or ICSI cycle needs. MACS is an optional extra sorting step, usually applied afterwards, that targets sperm with surface signals of damage. The laboratory rationale is understandable; the evidence for better outcomes is limited; and the decision belongs with you and your clinician, informed by a clear written quotation and a clear explanation of what the add-on does and does not change.

    Frequently asked questions

    Does MACS replace density gradient or swim-up preparation?

    Usually not. In the laboratories that offer it, MACS is applied after routine preparation, so the washing and concentration step still happens. Ask your clinic to describe its exact sequence if this matters to you.

    Will MACS improve my chance of pregnancy?

    That is not established. HFEA assesses sperm selection including MACS as having insufficient moderate- or high-quality evidence for improved chances of having a baby in male-factor infertility. Your clinician can explain what that means for your individual situation.

  • Preparing for PGT When a Chromosome Rearrangement Is Already Known

    A chromosome rearrangement on a report changes the PGT conversation in a specific way. You are not asking whether genetic testing exists in general. You are asking whether a laboratory can build a test around your rearrangement, how it will report the results, and what happens when the answer is unclear.

    That makes the first useful step a records step, not a booking step. Before a clinic can say anything meaningful about PGT for structural rearrangements (PGT-SR), it needs the actual laboratory report, not a summary such as “a balanced translocation was found.”

    Start with the report, not the diagnosis label

    PGT-SR is designed for people who carry a known chromosomal structural rearrangement. It addresses a different question from PGT-M, which concerns a known single-gene condition. The two tests are not interchangeable, and a treating team together with a genetic counsellor should review the relevant history, the test design and whether testing is suitable at all (HFEA: PGT-M and PGT-SR).

    In practice, that review begins with the karyotype or other cytogenetic report. Ask the genetics service or clinic that produced it for the full document, including the written interpretation, not only the conclusion line. If the finding came from a different technique, such as FISH or a microarray, request that report too, because the information it contains is not identical.

    Useful details to have in front of you:

    • The exact rearrangement named in the report, including the chromosomes involved and the described breakpoints
    • Whether it is described as balanced or unbalanced, and whether the report uses a different term
    • Whether the report states it was inherited or arose newly (de novo), and on what basis
    • Whether a partner has been tested, and whether that result is on file
    • Any prior pregnancy, miscarriage or products-of-conception testing records that relate to the rearrangement

    You do not need to interpret these documents yourself. The point is to arrive at the consultation with the source material rather than a remembered summary, so the clinician can work from the same facts you are working from.

    Questions that belong to the clinical team

    These are legitimate questions for a licensed clinician or genetic counsellor. Ask them directly, and ask for the answers in writing where you can, because PGT planning often spans several conversations and sometimes more than one clinic.

    About the rearrangement itself

    • Can you explain my rearrangement in plain language, including what it may mean for pregnancies?
    • Is it inherited, and should my partner or other family members be offered testing?
    • Does anything in my history change how you would approach PGT?

    About the test design

    • Has your laboratory validated a PGT-SR protocol for this specific rearrangement, rather than for rearrangements of this general type?
    • What information or samples do you need from me before the test can be designed?
    • How long does that preparation take, and does it need to happen before a stimulation cycle starts?

    About results and uncertainty

    • How will balanced and unbalanced results be reported, and in what wording?
    • What happens if a result is inconclusive or cannot be interpreted?
    • What does the report tell us about the sampled cells, and what can it not tell us about the whole embryo?
    • Would you recommend confirmatory testing during pregnancy, and how would that be arranged?

    That last group matters because a PGT result is a laboratory finding from a small sample, not a guarantee. PGT-A, the chromosome-number test, is described by the UK regulator as having limitations and as capable of producing incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA: PGT-A). The same caution applies to how you read any PGT report: treat it as information to discuss, not a verdict.

    Related reporting questions come up with mosaic findings, where an intermediate result is inferred from the biopsy sample. Technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo; the uncertainty should be discussed with the treating clinician and genetic counsellor (ASRM: mosaic PGT-A results). If your clinic mentions mosaicism alongside your rearrangement, ask how the two are being reported separately.

    Timing: what has to happen before what

    With a known rearrangement, the sequence usually matters more than the calendar. Test design and genetic counselling generally need to be settled before embryo testing can mean anything, and that preparation may involve records from a genetics service in your home country. Ask the clinic to lay out the order of steps and mark which ones depend on documents you still need to obtain.

    A practical way to hold this together is a simple two-column list: what the clinic must confirm, and what you must supply. Typical items on your side include the full cytogenetic report, partner testing status, prior pregnancy records and any previous PGT or prenatal reports. Typical items on the clinic side include whether their platform covers your rearrangement, how they report inconclusive results, and who provides genetic counselling and in what language.

    If you are comparing more than one clinic, compare those answers rather than headline claims. A general overview of PGT-SR for patients with structural chromosomal rearrangements can help you frame the same questions consistently across providers, and a comparison of PGT-A, PGT-M and PGT-SR is useful if you are still working out which test is being discussed. For the wider treatment sequence, see the step-by-step overview of PGT IVF in Thailand.

    Preparing for a remote consultation from abroad

    Many international patients have their first substantive conversation before travelling. That conversation is more useful when the clinic already has your records. Ask what format they prefer for scanned reports, whether translated summaries are needed, and who will read the file before the appointment.

    It also helps to agree, in advance, who answers what. A genetic counsellor may handle questions about the rearrangement and family testing; the fertility clinician may handle cycle planning; a coordinator may handle scheduling and document requests. Coordination support can include organising records, requesting appointments and confirming the format of a remote consultation, but clinical interpretation and any treatment decision stay with the treating team.

    Before you travel, confirm the appointment location, the language in which counselling will be provided, and whether any part of the test preparation must be completed in your home country. These are logistics questions, and they are worth settling early because they can affect when a cycle is realistically possible.

    After the cycle: results, handover and follow-up

    Ask in advance how results will be communicated, who will explain them, and what records you will receive to take home. If you plan to continue care with a clinician in your own country, ask what documentation they would find useful and request it before you leave. Confirmatory prenatal testing, if recommended, is arranged through your maternity pathway, so ask how that referral is expected to work.

    One reminder that applies throughout: keep your own dated copy of every report and do not change any medication on the basis of something you have read online. Questions about your diagnosis, your options, your risks and your individual chances belong with your licensed clinicians, and it is reasonable to keep asking until the answers make sense to you.

    Frequently asked questions

    Does a known rearrangement mean PGT is definitely right for me?

    Not automatically. PGT-SR is designed for people with a known structural rearrangement, but whether testing is suitable, and how it should be designed, depends on your specific report and history. A treating team and genetic counsellor should review those with you before you commit to a plan.

    What if my clinic has not tested this exact rearrangement before?

    Ask directly whether their laboratory has validated a protocol for your specific rearrangement, and what they would need from you to design one. If the answer is unclear, that is a reasonable point to seek a second clinical opinion before starting a cycle.

  • Questions to Ask a Genetic Counsellor About Combining PGT-M and PGT-A

    PGT-M and PGT-A are not two versions of the same test. PGT-M looks for a known single-gene condition that runs in a family; PGT-A looks at chromosome number in the embryo. When a clinic plans both, the laboratory is being asked to answer two separate questions from cells taken in a single biopsy. That is why the counselling conversation matters: it is where test design, limitations and reporting responsibilities get pinned down before any cycle begins.

    You do not need to arrive with technical knowledge. You do need to arrive with the right questions and the right records. Below is a way to organise both.

    Start with what each test is actually asking

    It helps to separate the two layers before discussing how they combine. PGT-M concerns a known monogenic condition, while PGT-SR concerns chromosomal structural rearrangements — a different question again. PGT-A assesses chromosome number in cells sampled from an embryo. Each test addresses a distinct question, and a treating team and genetic counsellor should discuss the relevant family history, test design and suitability for your situation.

    If you are still sorting out which test is which, a plain-language comparison of PGT-A, PGT-M and PGT-SR is a reasonable place to start before the appointment. The goal of the counselling session is not to re-learn definitions but to apply them to your family.

    Test design: the questions that shape the whole cycle

    Test design is where most of the practical uncertainty sits when two tests are combined. Ask these directly, and ask for the answers in writing if the appointment is remote.

    • Same sample or separate biopsies? Can the laboratory perform both the PGT-M and PGT-A analysis on the same trophectoderm sample, or would a second biopsy be needed? A second biopsy is not a neutral detail — embryo biopsy can cause damage and prevent further development, so the number of sampling events is worth clarifying.
    • How is the PGT-M assay built for our family? PGT-M testing is customised to a specific known condition and family variant. Ask how the assay is designed, what validation steps precede clinical use, and how long that preparation takes relative to your intended cycle dates.
    • Are linked markers needed, and what if we are uninformative? Some PGT-M designs rely on informative genetic markers flanking the variant. Ask whether your family’s results provide enough information, and what the laboratory does if they do not — for example, whether additional family samples would be requested.
    • How does whole-genome amplification interact with the two readouts? Both analyses typically begin from amplified DNA from the same few cells. Ask how the laboratory handles the possibility that amplification or the PGT-M assay itself affects the quality of the chromosome-number readout, and whether one test is prioritised if sample quality is limited.
    • What happens to embryos that are unaffected by the PGT-M result but abnormal on PGT-A? The two results can point in different directions. Ask in advance how such embryos would be classified and discussed.

    Limitations: what neither test can promise

    This is the part patients most often wish they had asked about earlier. A combined report can look authoritative while still carrying real uncertainty at both layers.

    PGT-A has recognised limitations and can produce incorrect findings. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample; technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo. In other words, the report describes the sample, not a confirmed diagnosis of the embryo.

    PGT-M carries its own boundaries. It addresses the specific variant the assay was designed for; it is not a general screen for other genetic conditions. Either layer can return a no-result or an inconclusive call, and the laboratory may or may not be able to re-test.

    Ask your counsellor to state plainly that neither test guarantees implantation, a successful pregnancy or a healthy child, and to explain what a no-result would mean for your decision-making before you are in the position of receiving one. If you want to prepare for that scenario specifically, the questions in the guide to no-result PGT reports pair well with this conversation.

    Reporting: who explains which part, and how

    A combined report has more than one section, and it is reasonable to ask who owns each one.

    • Which clinician or counsellor explains the PGT-M interpretation, and who explains the PGT-A interpretation?
    • If the two results are discordant or one is uninformative, who coordinates the discussion and in what timeframe?
    • What confirmatory testing during a later pregnancy might be discussed, and who would arrange it?
    • Which results will be released to you directly, and in what format?

    These are not bureaucratic questions. They determine whether you receive one coherent explanation or two partial ones. A useful companion read is the discussion of who should explain PGT findings and treatment options.

    Records to gather before the appointment

    Counselling about a combined test is only as specific as the information the counsellor has. Before a remote or in-person appointment, collect:

    • The genetic test report confirming the family variant, including the gene, the specific change and the laboratory that reported it.
    • Relevant family history, including which relatives are affected and how they are related to you.
    • Reports from any previous IVF or PGT cycles, including biopsy, amplification or no-result information.
    • Names and contact details of the clinicians who ordered the original genetic testing, in case the laboratory needs to follow up.

    If you are consulting a clinic in Thailand from abroad, it also helps to confirm the appointment format, the language of the consultation, whether an interpreter is needed, and how documents should be sent. A terminology worksheet prepared for a remote consultation can reduce misunderstandings about terms such as informative, no-result and mosaic.

    A worked planning example

    Suppose a couple knows the family variant and has an appointment with a counsellor six weeks before a planned cycle. A practical preparation sequence might look like this:

    1. Send the original genetic report and family history ahead of the appointment, and ask whether any relative’s sample would be needed for marker work.
    2. Ask in writing whether both tests can run on one biopsy sample, and what the laboratory’s fallback is if sample quality is limited.
    3. Ask for a short written summary of what a no-result, an inconclusive PGT-M call or a mosaic PGT-A result would each mean for next steps.
    4. Confirm which named clinician will explain each part of the report and how results reach you.
    5. Ask what the timeline for assay preparation means for your intended dates, and keep that answer with your cycle planning notes.

    None of these steps requires you to interpret a result yourself. They simply make sure the clinical team has what it needs and that you know where each answer will come from.

    Where coordination ends and clinical advice begins

    Patients can and should ask licensed clinicians about diagnosis, options, risks, reports and their individual chances — that is exactly what the counselling appointment is for. A patient coordination service works on a different layer: organising records, requesting appointments and remote consultation formats, clarifying language needs, and helping with follow-up communication after you return home. It does not interpret genetic results, advise on test choice or predict outcomes. If you would like help assembling records and questions before approaching a clinic, you can request a case review and the scope will be confirmed with you individually.

    Frequently asked questions

    Can PGT-M and PGT-A be done on the same embryo biopsy?

    That is a laboratory design question, and the answer depends on the clinic and the assay. Ask your counsellor or treating team directly whether both analyses can run on the same trophectoderm sample, and what the plan is if sample quality is limited. A second biopsy is not a trivial step, since embryo biopsy can cause damage and prevent further development.

    If PGT-M says an embryo is unaffected, does a PGT-A result still matter?

    They answer different questions. PGT-M addresses the specific family variant, while PGT-A looks at chromosome number in the sampled cells. A combined report can therefore contain two results that point in different directions. Ask in advance how such embryos would be classified and discussed, rather than deciding in the moment.

  • Why PGT-A and PGT-M Answer Different Genetic Questions

    Two embryos can both receive a “normal” result and still be tested for completely different reasons. That is the simplest way to understand why PGT-A and PGT-M are not interchangeable: they are built to answer different questions, using different laboratory designs, and each has its own blind spots.

    PGT-A asks whether an embryo’s cells show the expected number of chromosomes. PGT-M asks whether an embryo inherited a specific genetic variant that is already known to run in a family. Neither test is a general certificate of embryo health, and neither guarantees a pregnancy or a healthy child.

    What PGT-A is designed to look at

    PGT-A stands for pre-implantation genetic testing for aneuploidy. Aneuploidy means an abnormal number of chromosomes — for example, an extra copy or a missing copy of a particular chromosome. According to the HFEA’s patient information on PGT-A, the test assesses chromosome number in cells sampled from an embryo.

    That scope matters. PGT-A is a genome-wide count, not a search for a named condition. It does not know that a particular family carries a variant in a particular gene, and it is not designed to detect one. A PGT-A report may flag an abnormal chromosome count, or it may describe a mosaic finding — an intermediate result inferred from the biopsy sample. As the ASRM committee opinion on mosaic PGT-A results explains, technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo.

    So a reassuring PGT-A result means the biopsy did not show an abnormal chromosome count. It says nothing about a single-gene condition your family may carry.

    What PGT-M is designed to look at

    PGT-M stands for pre-implantation genetic testing for monogenic disorders — conditions caused by a variant in a single gene. The HFEA’s information on PGT-M and PGT-SR describes PGT-M as testing for a known monogenic condition, and notes that a treating team and genetic counsellor should discuss the relevant history, test design and suitability.

    That word “known” carries a lot of weight. PGT-M is not a scan for unknown problems. It is a targeted test built around a specific variant — or, in some designs, around linked markers near that variant — that has already been identified through prior testing of the family or the parents. The laboratory needs that information to build a reliable assay before it can report whether an embryo inherited the variant.

    Because the test is targeted, a PGT-M result tells you about that one condition. It does not confirm that the embryo’s chromosome number is normal across the genome. A separate test would be needed for that question.

    A side-by-side view

    Question PGT-A PGT-M
    What is being examined? Chromosome number across the genome Inheritance of a known familial variant
    Does it need prior family testing? No — it is not built around a family variant Yes — the assay depends on known variant information
    Can it rule out a known single-gene condition? No It is designed to address that condition, within the limits of the assay
    Can it confirm normal chromosome number? It assesses this, with limitations No
    Typical report language Aneuploid, euploid, mosaic, no result Variant present, variant absent, inconclusive, no result

    PGT-SR is a third category, used when a parent carries a chromosomal structural rearrangement rather than a single-gene variant. It is a distinct question again, and the HFEA source above groups it with PGT-M only to distinguish their separate purposes.

    Why a normal PGT-A result does not cover a family condition

    This is the point that most often causes confusion. A couple who knows they carry a variant for a single-gene condition may assume that a “normal” PGT-A result means the embryo is unaffected. It does not. PGT-A was never looking at that gene. The variant could be present in an embryo whose chromosome count looks normal on biopsy.

    The reverse is also true. An embryo reported as unaffected on PGT-M may still have an abnormal chromosome count, because PGT-M does not assess that. Each result answers its own question and leaves the other open.

    When the two tests are combined

    Some families are advised to consider both tests together: PGT-M for the known condition and PGT-A for chromosome number. Combining them can address two separate questions in one biopsy, but it is not automatically the right choice for everyone.

    It is worth asking your clinician what the combination adds in your situation, and what it costs — in biopsy material, laboratory analysis, time and counselling. A combined approach also means two sets of results to interpret, each with its own uncertainty. The decision belongs with your treating team and genetic counsellor, who can weigh your history and the test design.

    Limits that apply to both tests

    • Sampling, not the whole embryo. Both tests work from a small biopsy. A result describes the sample, and the ASRM opinion stresses that a sampled result does not establish the whole embryo’s cell composition.
    • Mosaicism. Intermediate PGT-A findings can be technically influenced and need careful discussion rather than a simple label.
    • No-result or inconclusive outcomes. Some biopsies do not yield a clear answer, and a repeat may or may not be possible.
    • Variants of uncertain significance. A variant’s link to disease is not always clear, which can complicate PGT-M design.
    • Residual risk. Neither test removes all uncertainty about an embryo or a pregnancy.
    • Biopsy itself carries a risk. The HFEA’s PGT-A questions and answers note that embryo biopsy can cause damage and prevent further development.

    Neither test guarantees a successful pregnancy or a healthy child, and neither is a required step for every patient. Whether testing is appropriate is an individual clinical decision.

    Preparing for a useful conversation about test design

    You can ask your clinician or genetic counsellor directly about diagnosis, options, risks, reports and your individual chances. A few preparation points help that conversation stay concrete:

    • Bring any prior genetic reports — the family variant, who was tested, and what the laboratory found.
    • Ask which test is being proposed and exactly what question it answers.
    • Ask what the report will and will not tell you, including how no-result and mosaic findings are handled.
    • Ask whether a combined approach is being considered and why.
    • Keep a dated record of what was discussed and what remains open.

    If you are comparing clinics or gathering information before a consultation, our guide to PGT-A, PGT-M and PGT-SR differences for international patients sets out the categories in more detail, and how to read PGT-A results covers report language. For families weighing a known condition, PGT-M versus PGT-A for single gene disorders goes further into that comparison.

    Coordination support can help with the practical side: organising records and prior genetic reports, requesting a remote consultation, planning travel around confirmed appointments, and arranging a records handover before you return home. Clinicians interpret results and make treatment decisions; the coordinating service does not diagnose or prescribe.

    Frequently asked questions

    If I have PGT-A done, do I still need PGT-M for a known family condition?

    They answer different questions. PGT-A assesses chromosome number and is not designed to detect a specific single-gene variant, so a normal PGT-A result does not rule out a known familial condition. Whether PGT-M is appropriate for you is a clinical decision for your treating team and genetic counsellor.

    Can PGT-M tell me whether an embryo's chromosomes are normal?

    No. PGT-M is targeted at a known variant and does not confirm chromosome number across the genome. If both questions matter in your situation, ask your clinician whether a combined approach is being considered and what it involves.

  • Embryology and Genetics Laboratories in PGT: Who Does What, and Where the Handoff Happens

    A PGT result looks like a single line on a report, but it is the product of two laboratories doing different jobs at different times. The embryology laboratory grows the embryo, takes the sample and keeps the embryo safe while it waits. The genetics laboratory amplifies that sample and interprets what it finds. Most of the confusion patients experience — why a result is inconclusive, why a report has two voices, why a quotation seems to cover “PGT” but not everything — comes from not knowing where one laboratory’s responsibility ends and the other’s begins.

    This guide walks through that relay step by step, then shows how to read a report and a quotation with the split in mind. It is general information, not a recommendation for your own case; questions about your embryos, your results and your options belong with the treating clinician and genetic counsellor.

    Why one test needs two laboratories

    PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations and can produce incorrect findings (HFEA: PGT-A). The cells that get tested are not the embryo itself — they are a few cells removed from it. Everything before that removal is embryology; everything after it is genetics. The two teams rarely share a bench, sometimes do not share a building, and in some arrangements do not share a country.

    That physical separation is normal and not a warning sign. What matters is that the handoff between them is controlled and documented.

    The embryology side: from fertilisation to a labelled tube

    The embryology laboratory’s PGT work begins well before any genetic question is asked.

    1. Culture to blastocyst. The embryo is grown in the laboratory until it reaches a stage where a sample can be taken. The day this happens is recorded, because it becomes part of the embryo’s identity in later reports.
    2. Biopsy. A small number of cells — typically from the trophectoderm, the outer layer that becomes the placenta rather than the baby — are removed. Biopsy is a real procedure with a real risk: HFEA patient information notes that embryo biopsy can cause damage and prevent further development (HFEA PGT-A FAQ). Ask your clinician what that risk means for your embryos specifically.
    3. Washing, tubing and labelling. The sampled cells are washed, placed in a tube and labelled so they can be traced back to one embryo and no other. This is unglamorous work and it is where identity errors would occur if controls failed.
    4. Vitrification of the biopsied embryo. The embryo is frozen while the sample travels. Its grade, biopsy day and freezing details are embryology observations — facts about the embryo, not conclusions about its chromosomes.

    Notice what the embryology laboratory does not do: it does not decide whether the embryo is chromosomally normal. It produces a sample and a record.

    The genetics side: from a few cells to a reported finding

    The genetics laboratory receives a tube of cells, not an embryo, and must turn that into an interpretable result.

    • Whole-genome amplification. A biopsy yields very little DNA, so it is copied many times over before analysis. This step is technically demanding and is one place where artefacts can enter.
    • Platform and resolution. The laboratory chooses a testing method and a resolution — how small a change it will report. Different platforms and resolutions answer different questions, which is why “PGT” alone is not a complete description of a test.
    • Matching the test to the question. PGT-A looks at chromosome number. PGT-M concerns a known monogenic condition, and PGT-SR concerns chromosomal structural rearrangements; these tests address different questions (HFEA: PGT-M and PGT-SR). PGT-M in particular usually requires preparatory work on the family’s genetic information before any embryo is tested, and that work sits on the genetics side.
    • Interpretation against the embryo’s reported data. The genetics team reads its findings alongside the embryology record — which embryo, which day, what was observed. A result is only meaningful when it is attached to the right embryo.
    • Reporting language. Reports use terms such as euploid, aneuploid, mosaic and inconclusive. Mosaic findings deserve particular care: a mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo (ASRM: mosaic PGT-A results). What a given report means for a transfer decision is a conversation with your clinician and genetic counsellor.
    • Quality assessment. Laboratories run internal and external quality checks. Whether these exist, and what they cover, is a fair question to ask before treatment.

    Where responsibility changes hands

    The interesting part of this split is the seams. Four handoff points are worth understanding:

    Handoff What should be controlled Why it matters to you
    Sample identity Labelling from biopsy through to report, with witnessing A result must belong to your embryo and no other
    Transport conditions How the sample travels, packaging, temperature, timing, documentation Degraded or mishandled samples can produce uninformative results
    Re-biopsy decision Who decides, on what basis, and what the embryo’s status is Re-biopsy is a clinical decision with its own risks, not a routine repeat
    Re-analysis decision Whether the stored sample can be retested and who authorises it Sometimes the sample, not the embryo, is the limiting factor

    An inconclusive result can originate on either side. The sample may have been too small or degraded (embryology and transport), or the amplification and analysis may not have produced a clear signal (genetics). A report that simply says “inconclusive” without indicating where the uncertainty arose is harder to act on. Ask your clinician whether the laboratory has explained the likely source.

    Reading a report that separates the two voices

    A well-structured report reads in two registers. The embryology section describes observations: embryo identifier, biopsy day, grade, freezing details. The genetics section states the finding, the platform, the resolution and any limitations. Keep the two apart in your mind. An embryology observation is not a genetic conclusion, and a genetic result does not describe embryo quality.

    If you are preparing for a consultation, it helps to bring the full report rather than a summary line, and to note which parts you want explained. If you would like help organising records and framing those questions before an appointment, the coordination service can assist with that practical preparation; interpretation of your results stays with your clinicians.

    Comparing quotations when two laboratories are involved

    Because the work is split, a quotation can be split too — and gaps hide at the seams. When you compare written quotations, check which laboratory performs which step rather than which provider sounds more impressive:

    • Is the biopsy included, and is it priced per embryo or per cycle?
    • Is the genetic analysis included for the number of embryos you realistically expect, and what happens to the price if more are biopsied?
    • Is transport to an external genetics laboratory included, and who arranges it?
    • Are re-analysis or re-biopsy charged separately?
    • Is genetic counselling before and after testing included?
    • Which laboratory issues the final report, and in what language?

    Our guide to comparing PGT IVF quotes in Thailand sets out a fuller checklist, and a separate article explains how to verify a hospital’s laboratory pathway for PGT. If you want to understand how accreditation claims are checked, see confirming accreditation scope at a Bangkok provider. For readers still mapping out provider options more broadly, a countrywide comparison of IVF hospitals and clinics is available as background reading; it is a research starting point, not a statement about outcomes.

    A worked planning example

    Suppose a couple is preparing for PGT-M after a known familial condition has been identified. Their preparation list might look like this: the genetics laboratory’s preparatory work on the family’s genetic information (genetics side, often weeks before stimulation); the embryology laboratory’s culture and biopsy plan, including how many embryos they are prepared to biopsy; the transport arrangement if the two laboratories are in different places; and the report format they will receive. None of these steps tells them whether PGT-M is right for them — that is a clinical and genetic-counselling discussion — but knowing the sequence means they can ask specific questions at each stage instead of discovering a gap later.

    PGT is not a guarantee of a successful pregnancy or a healthy child, and it is not necessary for every patient; whether to use it should be discussed for the individual situation (HFEA: PGT-A). Understanding the two-laboratory structure will not change that, but it will help you ask better questions of the people who can.

    Frequently asked questions

    If my PGT result is inconclusive, which laboratory is responsible?

    It can be either. An inconclusive result may reflect the sample itself — too few cells, degradation during handling or transport — or the amplification and analysis stage. Ask your clinician whether the laboratory has identified the likely source, and whether re-analysis of the stored sample is possible before considering anything further.

    Does the embryology laboratory decide whether an embryo is suitable for transfer?

    No. The embryology laboratory records observations such as biopsy day and embryo grade, and the genetics laboratory reports a finding from the sample. How those pieces combine into a transfer decision is a clinical judgement made with you by your treating team.

  • Piezo-ICSI vs Conventional ICSI: What the Difference Means for Your Treatment Plan

    ICSI, or intracytoplasmic sperm injection, is a laboratory step in which an embryologist picks up a single sperm and injects it into a mature egg. Piezo-ICSI is a variation on that step. The difference is not in what the procedure is trying to achieve, but in how the injection needle enters the egg.

    In conventional ICSI, the embryologist advances the injection pipette through the egg’s outer layers and membrane using manual control, often with a hydraulic or air-driven system. In Piezo-ICSI, the pipette is driven by a piezoelectric element that produces very fine, controlled vibrations. The needle tip is brought to the egg membrane and a small, precise movement is used to breach it, rather than pushing through in one continuous advance.

    That is the core mechanical distinction. Everything else — why a clinic might offer it, whether it changes your chances, and how it fits with genetic testing — follows from that difference and from the evidence available for it.

    What actually changes at the microscope

    During conventional ICSI, the embryologist must break the egg membrane to deliver the sperm. This is a delicate moment: the membrane can dimple and resist before it gives way, and the release of pressure can disturb the egg’s internal structure. The skill of the embryologist matters a great deal here.

    With Piezo-ICSI, the vibration is used to make a small opening at the point of contact. The idea is that less force and less deformation are applied to the egg. Proponents describe this as a gentler penetration step. It is a plausible mechanical rationale, and it is the reason the technique is discussed at all.

    What this article cannot tell you is how much that gentleness matters in your case. That depends on the eggs, the sperm, the laboratory, and the clinical history — questions for the treating team, not for a general guide.

    Why egg survival and fertilization are the focus

    The outcome most closely tied to the injection step is whether the egg survives the procedure and whether fertilization follows. Eggs vary in how robust their membranes are, and some are more fragile than others. In situations where a clinic is concerned about egg fragility or about fertilization results in a previous cycle, the way the needle enters the egg becomes a more relevant variable.

    This is where the discussion of indications usually begins. A clinic might consider Piezo-ICSI when there is a history of poor fertilization after conventional ICSI, when few eggs are available, or when the treating embryologist judges the eggs to be delicate. These are clinical judgements made with the full picture of your cycle, not rules that can be applied from a website.

    It is worth being clear about the limits of the evidence. The mechanical description of Piezo-ICSI is well established. Whether it improves live birth rates compared with conventional ICSI is a separate question, and one that should be answered by your clinic with reference to the evidence it relies on. Ask directly: what does the evidence show, and how does it apply to my situation?

    Indications: who a clinic might consider it for

    There is no universal list of indications that applies to every patient or every laboratory. The following are the kinds of situations in which the question tends to come up, and they should be discussed with a licensed clinician who can review your history:

    • Previous poor fertilization after a conventional ICSI cycle, where the team wants to examine whether the injection technique contributed.
    • Fragile or limited eggs, where the embryologist judges that a gentler penetration step may be preferable.
    • Small numbers of mature eggs, where each egg carries more weight in the cycle.
    • Laboratory preference or protocol, where a clinic uses Piezo-ICSI as its standard or offers it as an option for selected cases.

    None of these is a guarantee that Piezo-ICSI will be used, or that it will change an outcome. They are conversation starters. The decision belongs with the treating clinician and embryology team, who can see the eggs and the laboratory conditions in front of them.

    What to verify about a Thai laboratory

    If Piezo-ICSI matters to your planning, the first thing to establish is whether the laboratory you are considering actually offers it. Not every IVF laboratory has a piezo-driven injection system, and availability can differ between clinics and even between locations of the same group.

    Useful questions to put in writing before you commit to a cycle:

    • Does this laboratory perform Piezo-ICSI, and is the equipment on site?
    • Is it offered routinely, only for selected cases, or not at all?
    • Who decides whether it is used — the treating doctor, the embryologist, or both — and when in the cycle is that decision made?
    • If it is used, is there an additional charge, and is that charge included in the quoted package or billed separately?
    • What does the clinic’s own evidence and experience suggest about when it is appropriate?

    These are factual questions about services and billing. They are reasonable to ask before treatment, and the answers should be confirmed in writing rather than assumed from a website or a conversation.

    How this interacts with PGT planning

    If you are planning preimplantation genetic testing, the ICSI decision sits upstream of the testing. PGT-A assesses chromosome number in cells sampled from an embryo, and the biopsy happens later in the laboratory process. The way fertilization was achieved does not change what PGT-A is measuring, but it does affect how many embryos reach the biopsy stage.

    That is the practical link. A cycle that produces few fertilized eggs gives the laboratory less to work with, and the testing pathway has fewer embryos to assess. This is one reason the injection technique can feel consequential when embryo numbers are expected to be low. It is also why the conversation about Piezo-ICSI belongs with the conversation about whether PGT is appropriate for you at all.

    PGT-A has limitations. The HFEA notes that testing can produce incorrect findings and does not guarantee a successful pregnancy or a healthy child. A biopsy can also damage an embryo and prevent further development. These are reasons to discuss the testing decision carefully with your clinician and a genetic counsellor, not reasons to avoid the conversation.

    A practical way to organise the decision

    Rather than treating Piezo-ICSI as a standalone choice, place it in the sequence of decisions for your cycle:

    1. Clarify the fertilization plan. Ask whether conventional ICSI, Piezo-ICSI, or another approach is proposed, and why. The guide to choosing between IVF and ICSI is a useful starting point for the wider decision.
    2. Confirm laboratory capability and cost. Establish whether the technique is available, how it is selected, and whether it appears in the quotation. The article on what a typical IVF package in Thailand includes can help you read a quote critically.
    3. Connect it to the PGT decision. If testing is planned, ask how the fertilization approach affects the number of embryos likely to reach biopsy, and what happens if too few do.
    4. Record the answers. Keep dated notes of what was confirmed, by whom, and what remains open. This is especially useful if you are coordinating between a home clinic and a Thai hospital.

    If you are arranging a remote consultation, it helps to send your history and your specific questions in advance so the clinician can address the fertilization plan and the testing plan together. Coordination support can help organise those questions and the records that go with them; the clinical judgement stays with the treating team.

    Where the coordinator’s role ends

    Thailand PGT can help you prepare questions, organise records, coordinate appointment and remote-consultation requests, assist with travel and language needs around confirmed appointments, and help request records for follow-up after you return home. We do not diagnose, prescribe, interpret results, or decide which fertilization technique is right for you. Those decisions rest with licensed clinicians who can review your individual history.

    The most useful thing you can do at the research stage is to separate what is known from what needs confirming. The mechanical difference between Piezo-ICSI and conventional ICSI is clear. Whether it is available where you plan to treat, whether it is indicated for you, and what it costs are questions with specific answers that only the clinic can give — and they are worth asking before the cycle begins, not after.

    Frequently asked questions

    Is Piezo-ICSI always better than conventional ICSI?

    No. The two techniques differ in how the injection needle enters the egg, and Piezo-ICSI is described as a gentler penetration step. Whether that matters for a particular patient depends on the eggs, the laboratory, and the clinical history. Ask your treating clinician what the evidence shows for your situation rather than assuming one technique is superior.

    Does using Piezo-ICSI change what PGT-A measures?

    No. PGT-A assesses chromosome number in cells sampled from an embryo, and the biopsy happens after fertilization. The fertilization technique affects how many embryos may reach the biopsy stage, but it does not change what the test is measuring or its limitations.

  • Communicating With Your Clinic During Ovarian Stimulation in Thailand

    During ovarian stimulation, most of your contact with the clinic happens between appointments rather than inside them. You are injecting medication at home or in your hotel, attending monitoring scans and blood tests, and waiting for instructions that may change your dose. The quality of that back-and-forth depends less on how many messages you send than on whether both sides agreed in advance how, when and through whom information should travel.

    This guide is about the communication setup itself. Decisions about your dose, your scan results and whether a symptom needs medical attention belong to your treating clinicians; the practical task here is making sure their instructions reach you intact and that your reports reach them in a usable form.

    Agree the contact route before your first injection

    The most useful conversation you can have during stimulation often happens before it starts. Ask the clinic, at your planning appointment or in a message beforehand, which person or team you should contact for day-to-day questions, and through which channel. Clinics differ: some route everything through a coordinator or nursing line, others expect you to message the doctor directly, and some use a patient portal. Do not assume the channel used for booking is the channel used during treatment.

    Write down and confirm:

    • The named contact or team for routine questions, and a backup for days off.
    • The channel for non-urgent messages (phone, portal, email, messaging app) and the channel for anything urgent.
    • Expected reply windows for routine messages, and what to do if you have not heard back by the time your next dose is due.
    • Who relays results after monitoring, and whether that is the same person who answers general questions.
    • Language of communication and whether an interpreter is part of the routine or arranged on request.

    If you are still comparing clinics or preparing your first consultation, it helps to ask these questions early, because the answers tell you how much day-to-day coordination you will need to organise yourself. A general overview of IVF in Thailand for international patients can help you frame those early questions.

    Report symptoms in a structure the clinic can act on

    Clinicians can respond to a clear report far more easily than to a stream of separate messages. Before stimulation begins, ask your clinic what they want to know about and how quickly. Then use one consistent format for every report, so nothing important is left out when you are tired or anxious.

    A simple structure that works for most non-urgent updates:

    1. Identity and cycle day — your name, the date, and where you are in the stimulation schedule.
    2. What you noticed — the symptom in plain words, when it started, and whether it is getting better, worse or staying the same.
    3. What you have taken or changed — medications as prescribed, plus any other medicines, without altering your protocol on your own.
    4. What you want to know — for example, whether this is expected, whether you should come in earlier, or whether to continue as planned.

    Ask the clinic in advance which symptoms they want reported immediately and which can wait until the next monitoring visit. Symptoms such as increasing abdominal bloating, pain, nausea or breathlessness are the kind of thing patients are often told to raise promptly, but the threshold for urgency is a clinical judgement for your own team, not something to infer from a general article. If you are concerned about ovarian hyperstimulation syndrome specifically, the clinic should tell you what to watch for and where to go outside opening hours; background on OHSS risk during IVF in Thailand can help you prepare questions, but your team sets your personal plan.

    Understand how monitoring results and dose changes reach you

    Stimulation usually involves repeat monitoring, and results often lead to a change in dose or in the date of your next visit. The communication risk is not the result itself but the handover: a number relayed by phone, a dose adjusted verbally, a next appointment moved. Ask how results will be given to you — in person at the scan, by a call later, through a portal, or via your interpreter — and who is authorised to give them.

    When you receive an instruction, read it back in your own words and ask for confirmation. A short written summary is worth requesting: the current dose, the date and time of the next monitoring visit, and any change to your medication schedule. If the instruction arrives in a language you are not fully comfortable with, confirm it through the interpreter rather than relying on a translation app for anything involving numbers or timing.

    Keeping your own parallel record

    Keep a simple dated log: injections taken, monitoring visits, results as you understood them, instructions received and who gave them. This is not a substitute for clinic records, but it makes later questions far easier and helps you spot a message that never arrived. If you are balancing treatment with work, the same log helps you plan around monitoring visits; see balancing work and IVF treatment in Thailand.

    Arrange interpreter support for the moments that matter

    Interpreters are often used to relay instructions, and the arrangement works best when it is planned rather than improvised. Ask whether interpretation is provided by the clinic, whether you are expected to bring your own, and whether it covers phone calls as well as in-person visits. A phone call about a dose change is exactly the kind of exchange where a misunderstanding is costly.

    Practical points to settle:

    • Whether the same interpreter can follow your case across visits, so you are not re-explaining context each time.
    • Whether the interpreter joins monitoring visits and results calls, or only the initial consultation.
    • How you will reach the interpreter outside appointment times, if at all.
    • Whether written instructions can be provided in English alongside any local-language version.

    During interpreted conversations, ask the clinician to speak to you rather than about you, and ask the interpreter to relay your questions exactly. After the conversation, repeat back what you understood and have the interpreter confirm it with the clinician. If you need help organising language support around confirmed appointments, that is a coordination task rather than a clinical one, and it can be discussed as part of Thailand travel and language assistance.

    Plan for the days when you are not in the clinic

    Stimulation rarely stays inside clinic hours. Ask what happens at weekends and public holidays, who covers urgent calls, and which hospital or emergency route to use if the clinic is closed. Confirm this in writing if you can, and keep it where you will find it quickly. If you are travelling between cities or staying somewhere without reliable phone signal, tell the clinic in advance so they can agree an alternative way to reach you.

    It also helps to decide who else may speak to the clinic on your behalf — a partner, a relative, or a coordinator — and to confirm with the clinic what consent they need before discussing your information with that person. Privacy arrangements vary, and it is better to settle them before a message goes to the wrong person.

    Hand over records and questions before you return home

    If your stimulation and monitoring continue after you leave Thailand, or if follow-up happens with a clinic at home, the communication task shifts to records. Before departure, ask for a summary of your stimulation course, monitoring results and instructions, and confirm who will send it, to whom, and by what method. Agree the recipient and the sharing method yourself rather than leaving it open.

    List any questions that remain unanswered and who is responsible for answering them. Clinicians interpret results and give medical instructions; a coordination service can help organise records and relay questions, but it does not diagnose or prescribe. If you want support requesting records and coordinating follow-up questions after you return home, that falls within records handover and follow-up communication.

    A short setup checklist

    • Named routine contact, backup contact and channel confirmed before the first injection.
    • Urgent-contact route and out-of-hours instructions written down.
    • Agreed symptom-reporting format and the clinic’s own list of what to report promptly.
    • Confirmed way that monitoring results and dose changes will be relayed, and by whom.
    • Interpreter arrangement agreed for phone and in-person updates.
    • Read-back habit in place for every instruction involving numbers or timing.
    • Dated personal log started and kept up to date.
    • Consent for any third party to speak with the clinic confirmed.
    • Records handover recipient and method agreed before you leave Thailand.

    None of this replaces your treating team’s judgement. It simply makes sure that when they give you an instruction, you receive it clearly, understand it, and can show that you followed it.

    Frequently asked questions

    Can I use a messaging app to contact my clinic during stimulation?

    Many clinics do, but the channel is a clinic-specific arrangement rather than a general rule. Ask before stimulation which channel is used for routine questions, which is used for urgent matters, and what reply time to expect. Confirm that the person monitoring that channel is authorised to relay clinical instructions, and keep a written record of anything agreed there.

    Do I need an interpreter for every appointment during stimulation?

    Not necessarily. Ask the clinic which contacts involve detailed instructions — results calls and dose changes are the obvious ones — and arrange interpretation for those. If the same interpreter can follow your case across visits, instructions are less likely to be misheard or re-explained. Confirm whether interpretation covers phone calls as well as in-person visits.

    How do I report side effects without sounding alarmist or underplaying them?

    Use one consistent structure: your identity and cycle day, what you noticed and when, whether it is changing, what medication you are taking, and what you want to know. Ask the clinic in advance which symptoms they want reported immediately. Whether a symptom is expected or urgent is a clinical judgement for your own team, so describe it plainly and let them decide.

  • Surgically Retrieved vs Ejaculated Sperm: How the Source Changes IVF Planning

    The difference between ejaculated and surgically retrieved sperm is easiest to understand as a difference in logistics rather than a difference in embryos. Both sources can provide sperm for fertilisation. What changes is how the sample reaches the laboratory, whether a surgical procedure has to be scheduled, and which lines appear in your quotation. What does not change is the day-to-day biology of embryo development, which is what determines when a biopsy for preimplantation genetic testing (PGT) can happen.

    This guide is written for international patients in the research stage who are comparing pathways and trying to read quotations accurately. It does not recommend one sperm source over another; that conversation belongs with the treating clinician and, where relevant, a urologist.

    Start with the practical difference: how the sperm reaches the lab

    Ejaculated sperm is collected on or around the day of egg retrieval, usually at the clinic, and prepared in the laboratory before insemination. Surgically retrieved sperm is obtained in an operating or procedure setting — commonly described as TESA, PESA or micro-TESE — and then either used fresh or frozen for a later cycle.

    That single difference cascades into three planning questions:

    • Timing: does the retrieval procedure need to coincide with egg retrieval, or can it be done and frozen in advance?
    • Procedure burden: does the plan include an additional procedure, anaesthesia and recovery time, and possible urology involvement?
    • Quotation structure: which fee lines exist in one pathway but not the other?

    Why surgically retrieved sperm is essentially always paired with ICSI

    With ejaculated sperm, the laboratory can choose between conventional insemination, where sperm and eggs are placed together, and intracytoplasmic sperm injection (ICSI), where a single sperm is injected into an egg. With surgically retrieved sperm, ICSI is the standard route, because the number of usable sperm available is limited and each one is handled individually.

    This matters for planning in a very concrete way: if your pathway involves surgical retrieval, treat ICSI as part of the baseline plan rather than an optional add-on. Ask for the ICSI fee to be shown as a separate, clearly labelled line so you can see what the retrieval pathway actually costs as a whole.

    It is also worth knowing that add-on sperm selection techniques exist and are marketed in some settings. The HFEA, the UK fertility regulator, reports insufficient moderate- or high-quality evidence to say whether techniques such as IMSI or MACS improve the chance of having a baby, including in male-factor infertility, and notes that sperm DNA fragmentation test methods and interpretations are not standardised. If a quotation includes such a technique, ask what question it is meant to answer in your case rather than assuming it is required.

    The scheduling dependency: fresh versus frozen retrieved sperm

    This is where most of the planning effort sits. A surgical retrieval can be timed to the egg retrieval cycle so that fresh sperm is available, or it can be performed earlier and the sperm frozen and stored. Each option creates different dependencies:

    Planning point Retrieval timed to egg collection Retrieval done in advance and frozen
    Number of procedures in the trip Retrieval and egg collection fall in the same window Retrieval may sit in an earlier trip or earlier date
    Recovery and travel Recovery overlaps with the IVF cycle itself Recovery can be separated from the stimulation cycle
    Dependency on a successful retrieval Outcome known only within the cycle Whether usable sperm were stored is known before the cycle starts
    Fee lines to confirm Retrieval fee, anaesthesia, ICSI, same-cycle laboratory handling Retrieval fee, freezing, storage, later thaw and ICSI

    The table is a planning framework, not a recommendation. Which route suits a given situation depends on clinical history, prior retrieval results and the treating team’s assessment — questions for the clinician and urologist, not for a coordination service.

    For international patients, the frozen-in-advance route has an obvious logistical attraction: it can reduce the number of things that must go right inside a single travel window. The trade-off is that freezing, storage and later thawing become their own fee lines and their own coordination tasks, including confirming how long storage is covered and what happens if the cycle is postponed.

    What does not change: embryo culture, biopsy day and PGT workflow

    Once fertilisation has happened, the laboratory’s schedule is driven by embryo development, not by where the sperm came from. Embryos are cultured, and if PGT is planned, a biopsy is taken at the stage the laboratory works with, with results reported afterwards.

    Two points are worth holding onto here. First, PGT is a set of tests with limitations, not a guarantee. The HFEA notes that PGT-A assesses chromosome number in sampled cells, that testing can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. Second, a reported finding describes the sampled cells; it does not establish the cell composition of the whole embryo, and technical factors can contribute to intermediate findings. Those are conversations for the treating clinician and genetic counsellor.

    There is also a procedural risk to acknowledge: the HFEA notes that embryo biopsy can cause damage and prevent further development. That risk exists regardless of sperm source, and it belongs in your discussion about whether to test at all.

    If your plan involves a known inherited condition or a chromosomal structural rearrangement, the relevant test is PGT-M or PGT-SR respectively, and test design depends on the specific history. A step-by-step guide to PGT-M planning in Thailand for known genetic disorders explains how that design conversation is usually organised.

    Reading a quotation when the sperm source differs

    Quotations for these two pathways are not directly comparable line by line, because they describe different sets of tasks. A useful approach is to rebuild both into the same categories before comparing totals:

    1. Cycle and monitoring fees — usually similar in structure.
    2. Fertilisation method — conventional insemination or ICSI; ICSI should be explicit in a retrieval pathway.
    3. Surgical retrieval — procedure fee, anaesthesia, theatre or facility charges, and any urology involvement.
    4. Freezing and storage — present in the frozen-retrieval route, and possibly also for embryos.
    5. Embryology and PGT — biopsy, testing and reporting, which should be quoted the same way in both pathways.
    6. Medication, travel and accommodation — often quoted separately or not at all.

    Mark every line you cannot confirm as unconfirmed rather than estimating it. A quotation with clearly flagged gaps is more useful for decision-making than a tidy total built on assumptions. If you are also weighing how embryos are transferred, fresh versus frozen embryo transfer pathways explains why the transfer stage may be planned separately from the retrieval stage.

    Records worth gathering before you ask for a quotation

    Hospitals can only quote and plan against the information they have. For a sperm-source question, the useful file usually includes:

    • Previous semen analysis reports, with dates and the reference ranges used by the issuing laboratory.
    • Any prior surgical retrieval record, including the technique used and whether sperm were found and stored.
    • Urology letters, imaging or diagnosis notes relevant to sperm production or obstruction.
    • Genetic reports for the patient or partner, where a known condition or rearrangement is being investigated.
    • A short dated timeline of previous cycles, so the team can see what was done and when.

    Keep the originals and send copies. A dated checklist of what you have sent, and what is still outstanding, prevents the same document being requested twice and makes remote consultation preparation much faster.

    Where coordination helps — and where it stops

    Coordinating a retrieval pathway involves several parallel threads: comparing what each quotation includes, organising records, requesting a remote consultation with the right specialist present, and planning travel around confirmed appointments. A coordination service can help with those tasks — assembling a question list, marking unconfirmed quotation fields, requesting documents, and arranging the appointment format and language support.

    What it cannot do is tell you whether surgical retrieval is appropriate, interpret a semen analysis or genetic report, or predict fertilisation. Those are clinical judgements. Patients are entitled to ask their treating clinician directly about expected fertilisation with fresh versus frozen retrieved sperm, the risks of the retrieval procedure, and what the alternatives are.

    If male-factor infertility is the reason surgical retrieval is being considered, male factor infertility treatment options in Thailand sets out the wider decision context. Where donor sperm is part of the picture instead, the guide to IVF with donor sperm in Thailand covers the separate planning and consent questions that pathway raises.

    A worked planning sequence

    As an illustration of how the pieces fit together — not a clinical protocol — a patient comparing the two pathways might work in this order:

    1. Collect prior semen analyses, any retrieval history and relevant urology or genetic letters into one dated folder.
    2. Write down the specific questions: is fresh or frozen retrieved sperm being considered, and why; what does the retrieval involve; what would change the plan.
    3. Request a remote consultation and ask which specialists will attend, so the urology questions are not deferred to a second appointment.
    4. Ask for quotations for both pathways using the same category headings, and mark unconfirmed lines.
    5. Identify which fee lines depend on travel dates — storage duration, additional trips, rescheduling terms.
    6. Confirm, in writing, what happens to stored sperm if the cycle is delayed, and who to contact about it.
    7. Before returning home, request the treatment records and agree how follow-up questions will be handled.

    The core answer, in one line: sperm source changes the procedure, the schedule and the quotation structure, while embryo culture and any PGT workflow continue to follow embryo development. Plan the logistics around that distinction, and leave the clinical choice to the team that knows your history.

    Sources: Embryo biopsy can cause damage and prevent further development. — HFEA PGT-A frequently asked questions (checked 2026-10-15).

    Frequently asked questions

    Does using surgically retrieved sperm mean PGT is required?

    No. PGT is a separate decision based on the reason testing is being considered, such as a known inherited condition, a chromosomal rearrangement, or chromosome-number screening after discussion with the treating team. Sperm source does not by itself determine whether testing is appropriate, and PGT has limitations that should be discussed before a cycle.

    Can surgically retrieved sperm be frozen so the retrieval happens on a different trip?

    Freezing retrieved sperm is a recognised option in some pathways, but whether it suits a particular situation depends on the clinical history and the treating team's assessment. Ask the clinician and urologist directly, and confirm the freezing, storage and thaw fee lines and storage duration in writing before committing to travel.

  • Sperm DNA Fragmentation Testing at an Older Paternal Age: What to Ask

    Sperm DNA fragmentation testing is often raised when a couple is planning IVF and the father is older. The useful question is not simply whether the test exists or what it costs, but whether it is indicated in your situation, what the number actually measures, and what you and your clinician would do differently depending on the result. A test that does not change a decision is worth questioning before you pay for it.

    This guide sets out the questions worth bringing to a consultation, in roughly the order they tend to matter. It does not tell you whether you need the test. That is an individual clinical judgement, and it belongs with a licensed clinician who has your history, semen analysis and treatment record.

    Start with the indication, not the test

    Age alone is a weak reason to order a test. Paternal age is relevant to fertility planning, but a clinician is likely to weigh it alongside other findings rather than treat a birthday as a stand-alone indication. Ask directly: In my case, what specifically makes sperm DNA fragmentation testing worth considering, and what would make you skip it?

    Triggers that are commonly discussed in this context include:

    • Recurrent pregnancy loss where no other explanation has been found
    • Repeated IVF cycles with poor fertilisation, poor embryo development or repeated implantation failure
    • Abnormal semen parameters on one or more analyses
    • A clinical varicocele or other male-factor diagnosis under evaluation
    • Planning a treatment step where sperm selection method is genuinely open to choice

    These are conversation starters, not a checklist that decides anything. The point of asking is to hear your clinician’s reasoning, including the possibility that the answer is “not indicated yet”. A clear “no, and here is why” is a useful answer.

    What the test measures, and what it does not

    Sperm DNA fragmentation testing estimates the proportion of sperm with damaged or broken DNA strands. It is a separate measurement from sperm count, motility and morphology, and it is separate again from the chromosomal status of an embryo.

    Two misunderstandings are worth clearing up early:

    • It is not an aneuploidy test. A fragmentation result does not tell you whether an embryo has the wrong number of chromosomes, and it does not replace preimplantation genetic testing for aneuploidy (PGT-A) if that is being considered for separate reasons.
    • It is not a fertility score. A result does not predict whether a given couple will or will not have a baby, and it should not be presented to you as one.

    If PGT-A is already part of your planning, the two discussions can sit side by side without one substituting for the other. The article on PGT-A and advanced paternal age covers that separate decision.

    Ask how the test is done and how the cut-off was set

    Laboratory method matters more than many patients expect. The UK fertility regulator, the HFEA, notes that sperm DNA fragmentation test methods and their interpretation are not standardised. That has a practical consequence: a number from one laboratory is not automatically comparable with a number from another, and a single threshold does not mean the same thing everywhere.

    Useful questions include:

    • Which assay does your laboratory use, and what is its own reference range?
    • Is the result reported as a percentage with a stated cut-off, and how was that cut-off established?
    • How much does a result near the threshold vary between samples from the same person?
    • If the first result is borderline or high, would you repeat it before acting on it, and after how long?

    You are not looking for a single “correct” number. You are checking whether your clinician treats the result as a stable measurement or as one imperfect data point among several.

    What a high result could actually change

    This is the question that decides whether the test earns its place in your plan. Ask your clinician to walk through the realistic options if the result comes back high, and to say plainly which of them have good supporting evidence and which do not.

    Areas that are commonly discussed include:

    • General health and lifestyle review — for example smoking, heat exposure, sleep, weight and other modifiable factors, discussed with your clinician rather than self-prescribed.
    • Antioxidant or other supplements — ask whether there is evidence that a particular supplement changes outcomes that matter to you, and whether any interaction with your other medication is a concern.
    • Sperm selection techniques — for example magnetic-activated cell sorting (MACS), which the HFEA describes as using magnetic sorting to separate sperm by surface signals associated with damaged or dying cells. The same HFEA guidance assesses sperm selection following sperm DNA fragmentation testing, including MACS, as having insufficient moderate- or high-quality evidence for improving the chance of having a baby in male-factor infertility. Ask your clinic how it presents this, and whether it would charge extra for it.
    • Surgical sperm retrieval — sometimes raised where fragmentation is high and other options are limited; ask about the evidence, the risks and whether it fits your situation.
    • Timing and technique of ICSI — ask whether the result would change how or when the laboratory handles the sample.
    • Whether PGT-A remains relevant — a fragmentation result does not answer the aneuploidy question, so ask how the two decisions interact in your plan.

    If none of these would change for you, that is important information. It may mean the test adds cost and anxiety without altering the plan.

    Ask who interprets the report, and get a copy

    A result without interpretation is easy to misread, especially when the assay and cut-off are unfamiliar. Before testing, confirm:

    • Who will explain the result to you, and in what format — a scheduled consultation, a written summary, or both?
    • Will the laboratory report be released to you, and in what language?
    • If you are consulting remotely from abroad, how will the result discussion be arranged and at what cost?
    • Who holds the report if you continue treatment elsewhere, and how would it be transferred with your consent?

    If you are gathering records before a first consultation, the guide to male fertility testing for international couples explains what tends to be useful to bring. For the practical side of sample and partner preparation, see the PGT IVF partner and sperm requirements checklist.

    Practical coordination questions

    Once the clinical questions are settled, the logistics are straightforward but worth confirming in writing:

    • What is the total cost of the test, including any repeat sample, consultation to discuss the result, and any add-on sperm selection?
    • What is the turnaround time, and does it fit your treatment dates or travel window?
    • Can the sample be produced locally and shipped, or does it need to be given at the clinic?
    • If you are travelling to Thailand, does the result need to be available before a treatment decision, or can planning proceed in parallel?

    Coordination support can help organise these questions, request the report and arrange a remote consultation, but the interpretation and any treatment recommendation come from your clinician. If you would like help preparing a question list and comparing what different clinics include, you can request a case review.

    A worked planning example

    Consider a couple where the father is in his late forties, there has been one miscarriage, and the semen analysis is within normal limits. Rather than booking the test immediately, they ask three questions at consultation: what in our history suggests fragmentation is contributing; what would we do differently if the result were high; and would we repeat a borderline result before acting on it. The clinician explains that with a single miscarriage and normal parameters, the test is unlikely to change the plan, and that if a high result appeared, the main discussion would be about sperm selection with limited supporting evidence and about general health factors. The couple decide to defer the test and revisit it only if further cycles fail. That is a legitimate outcome of asking.

    In another situation — repeated failed cycles with no clear explanation — the same questions may lead to testing, a repeat if borderline, and a documented discussion of what would change. The difference is the indication, not the age.

    What to leave the consultation with

    • A plain statement of why the test is or is not indicated for you
    • The assay, reference range and repeat policy in writing
    • A list of what would change if the result were high, with the strength of evidence noted
    • The name of the clinician who will interpret the result and how you will receive it
    • Costs, turnaround and record-transfer arrangements confirmed

    Older paternal age is a reasonable prompt to ask questions. It is not, by itself, an answer about whether this particular test belongs in your care.

    Frequently asked questions

    Does older paternal age on its own mean I should have sperm DNA fragmentation testing?

    Not automatically. Age is one factor a clinician may weigh alongside your history, semen analysis results and any previous cycles. Ask what specifically in your case makes the test worth considering, and what would make your clinician skip it.

    If my sperm DNA fragmentation result is high, does that mean we need PGT-A?

    No. Fragmentation testing looks at DNA damage in sperm, while PGT-A looks at the chromosomal status of an embryo. They answer different questions, and a fragmentation result neither requires nor replaces PGT-A. Ask your clinician how each decision fits your plan.